Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Documenta Ophthalmologica
Published in: Documenta Ophthalmologica 3/2019

01-06-2019 | Zonisamide | Original Research Article

Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin

Authors: Xiang Ji, Michelle McFarlane, Henry Liu, Annie Dupuis, Carol A. Westall

Published in: Documenta Ophthalmologica | Issue 3/2019

Login to get access

Abstract

Purpose

The anti-epileptic drug vigabatrin is associated with reduction in light-adapted 30-Hz flicker electroretinogram (ERG) amplitude. Ophthalmological assessments, including ERGs, monitor retinal health during vigabatrin treatment. RETeval™ is a hand-held ERG device adapted for dilation-free ERG assessment. To evaluate the usefulness of RETeval™ for vigabatrin ERG assessment, we evaluated intra-visit reliability and clinical feasibility of RETeval™ ERG assessment in children under 3 years of age undergoing vigabatrin treatment.

Methods

In this prospective study, children underwent 30-Hz flicker ERG assessment with RETeval™ before routine vigabatrin monitoring including sedated-ERG using the Espion E2 Colour Dome. Intraclass correlation coefficient (ICC) statistics identified the degree of intra-visit reliability from two repeated measurements of the same participant within one testing session. The omega squared (ω2) statistic identified the level of association between RETeval™ and Espion light-adapted 30-Hz flicker responses.

Results

Nine children completed RETeval™ ERG testing. The intra-visit ICCs for the RETeval™ 30-Hz flicker amplitude (µV) were high: 0.81 (right eye) and 0.86 (left eye), while the implicit times (ms) were 0.79 (right eye) and 0.42 (left eye). The RETeval™ 30-Hz flicker amplitude was positively associated with the Espion 30-Hz flicker response (ω2 = 0.71). The Bland–Altman plot showed no bias in the mean difference of amplitudes between the two systems.

Conclusion

This is the first study to assess the utility of RETeval™ device in children under 3 years of age undergoing vigabatrin treatment. RETeval™ demonstrated high intra-visit reliability with responses consistent with the standard Espion ERG. RETeval™ may be beneficial for assessment of retinal toxicity in young children treated with vigabatrin.
Literature
1.
Riikonen R, Donner M (1979) Incidence and aetiology of infantile spasms from 1960 to 1976: a population study in Finland. Dev Med Child Neurol 21:333–343CrossRefPubMed
2.
Sidenvall R, Eeg-Olofsson O (1995) Epidemiology of infantile spasms in Sweden. Epilepsia 36:572–574CrossRefPubMed
3.
Rantala H, Putkonen T (1999) Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 40:286–289CrossRefPubMed
4.
5.
Chiron C, Dumas C, Jambaqué I et al (1997) Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 26:389–395CrossRefPubMed
6.
Jones K, Go C, Boyd J et al (2015) Vigabatrin as first-line treatment for infantile spasms not related to tuberous sclerosis complex. Pediatr Neurol 53:141–145CrossRefPubMed
7.
Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180–181CrossRef
8.
9.
Harding GF, Wild JM, Robertson KA et al (2000) Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Am J Ophthalmol 55:347–352
10.
Good WV (2011) Measuring field loss in children administered vigabatrin: a problem in search of a solution. J AAPOS 15:411–412CrossRefPubMed
11.
McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12CrossRef
12.
Westall CA, Wright T, Cortese F et al (2014) Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study. Neurology 83:2262–2268CrossRefPubMedPubMedCentral
13.
Sun L (2010) Early childhood general anaesthesia exposure and neurocognitive development. BJA Br J Anaesth 105:i61–i68CrossRefPubMed
14.
Zhang H, Du L, Du Z et al (2015) Association between childhood exposure to single general anesthesia and neurodevelopment: a systematic review and meta-analysis of cohort study. J Anesth 29:749–757CrossRefPubMed
15.
Davidson AJ, Becke K, De Graaff J et al (2015) Anesthesia and the developing brain: a way forward for clinical research. Paediatr Anaesth 25:447–452CrossRefPubMed
16.
Kato K, Kondo M, Sugimoto M et al (2015) Effect of pupil size on flicker ERGs recorded with RETeval system: new mydriasis-free full-field ERG system. Investig Ophthalmol Vis Sci 56:3684–3690CrossRef
17.
Grace SF, Lam BL, Feuer WJ et al (2017) Nonsedated handheld electroretinogram as a screening test of retinal dysfunction in pediatric patients with nystagmus. J AAPOS 21:384–388CrossRefPubMed
18.
Al-Otaibi H, Al-Otaibi MD, Khandekar R et al (2017) Validity, usefulness and cost of RET eval system for diabetic retinopathy screening. Transl Vis Sci Technol 6:3CrossRefPubMedPubMedCentral
19.
Miura G, Nakamura Y, Sato E, Yamamoto S (2016) Effects of cataracts on flicker electroretinograms recorded with RETevalTM system: new mydriasis-free ERG device. BMC Ophthalmol 16:22CrossRefPubMedPubMedCentral
20.
Asakawa K, Amino K, Iwase M et al (2017) New mydriasis-free electroretinogram recorded with skin electrodes in healthy subjects. Biomed Res Int 2017:1–7CrossRef
21.
Liu H, Ji X, Dhaliwal S et al (2018) Evaluation of light- and dark-adapted ERGs using a mydriasis-free, portable system: clinical classifications and normative data. Doc Ophthalmol 137:169–181CrossRefPubMed
22.
Davis CQ, Kraszewska O, Manning C (2017) Constant luminance (cd·s/m2) versus constant retinal illuminance (Td·s) stimulation in flicker ERGs. Doc Ophthalmol 134:75–87CrossRefPubMedPubMedCentral
23.
Nakamura N, Fujinami K, Mizuno Y et al (2016) Evaluation of cone function by a handheld non-mydriatic flicker electroretinogram device. Clin Ophthalmol 10:1175–1185CrossRefPubMedPubMedCentral
Metadata
Title
Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin
Authors
Xiang Ji
Michelle McFarlane
Henry Liu
Annie Dupuis
Carol A. Westall
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
Documenta Ophthalmologica / Issue 3/2019
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-019-09684-9

Other articles of this Issue 3/2019

Documenta Ophthalmologica 3/2019 Go to the issue

Original Research Article

Semi-invasive and non-invasive recording of visual evoked potentials in mice

Letter to the Editor

Reply to: Diagnosing MELAS requires not only an mtDNA variant but also an appropriate phenotype

ISCEV Standards

ISCEV extended protocol for the stimulus–response series for the dark-adapted full-field ERG b-wave

ISCEV Standards

ISCEV extended protocol for the stimulus–response series for light-adapted full-field ERG

Original Research Article

Corosolic acid: antiangiogenic activity and safety of intravitreal injection in rats eyes

Clinical Case Report

Novel biallelic loss-of-function KCNV2 variants in cone dystrophy with supernormal rod responses